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Background. Frequent and rapid development of myelopathy has been reported in in-
dividuals with human T-lymphotropic virus type 1 (HTLV-1) infection following solid
organ transplantation. There is no information regarding HTLV-2, a closely related virus
that often infects injection drug users.
Methods. This study includes a retrospective analysis of all consecutive organ transplants
performed during the last 2 decades at a large reference transplantation unit in Spain. All
participants were tested for anti-HTLV antibodies.
Results. A total of 2019 individuals were tested for HTLV during the study period,
including 663 potential donors and 1356 recipient candidates. Twelve (0.59%) were
reactive on initial HTLV serologic screening, but only 6 (all recipients) were confirmed as
positive, all for HTLV-2. Two recipients underwent liver transplantation and have
remained asymptomatic despite being on tacrolimus for 4 and 8 years, respectively.
Likewise, the remaining 4 HTLV-2 carriers have not developed clinical complications
potentially associated with HTLV-2.
Conclusions. Unlike HTLV-1 infection, HTLV-2 infection in the transplantation setting
does not seem to be associated with rapid development of neurologic complications, Given
the cross-seroreactivity between HTLV-1 and HTLV-2, discriminatory rapid tests are
urgently needed and would reduce unnecessary organ discharge.*Address correspondence to Dr Vicente Soriano, University
International La Rioja Health Sciences School and Medical
Center, calle Almansa 101, Madrid 28040, Spain. Tel: þ34
659687981. E-mail: vicente.soriano@unir.netHUMAN T-lymphotropic virus type 1 (HTLV-1) andtype 2 (HTLV-2) are retroviruses that infect roughly
10 to 15 million people globally. Infection with HTLVs has
been associated with the development of hematologic and
neurologic conditions, although the evidence for pathoge-
nicity is significantly lower for HTLV-2 than for HTLV-1
[1e3]. Even so, only 10% of HTLV-1 carriers may develop
any of the 2 lifelong characteristic clinical conditions, known
as HTLV-associated myelopathy and T-cell leukemia/
lymphoma.
Recent reports have highlighted an increased disease risk
in people infected with HTLV-1 following solid organ
transplantation [4]. Indeed, rapid development of subacute
myelopathy has been reported in more than 40% of these
patients [5,6]. Viral infection may be present in the recipient
before transplantation or may have occurred as result of
transmission from the infected donor. In either of these
situations, the administration of immunosuppressants seemsAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
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ion Proceedings, XX, 1e3 (2020)to play an important role in driving rapid clinical progres-
sion [7]. Based on these observations, HTLV screening has
been requested for both donors and recipients before
transplantation [8].
Current HTLV serologic screening assays do not distin-
guish between HTLV-1 and HTLV-2. Collection of this
information requires further testing using immunoblot and/
or nucleic acid testing [9]. In the transplantation setting of
using cadaveric donors, immediate results of testing are very
valuable. Given that no information has been released so far
on clinical outcomes for HTLV-2 in the transplant setting,0041-1345/20
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Table 1. Main Features of the HTLV Population in Spain
HTLV-1 HTLV-2 P Value
No. 389 807 n.s.
Median age in years (range) 41 (3-78) 35 (14-71) n.s.
Male sex 135 (34.7%) 613 (76%) <.001
Country of origin: Spain, Latin America, Africa 65 (16.7%), 254 (65.3%), 43 (11%) 730 (90.4%), 21 (2.6%), 14 (1.7%) <.001
Major route of infection: Heterosexual, men having sex
with men, injection drug use
124 (31.5%), 6 (1.5%), 12 (3%) 32 (3.9%), 0, 609 (75.5%) <.001
HIV co-infection 24 (6.2%) 668 (82.8%) <.001
Major clinical manifestations: Myelopathy, T-cell
lymphoma
45 (11.6%), 27 (6.9%) 1, 0 <.001
Abbreviations: HIV, human immunodeficiency virus; HTLV-1, human T-lymphotropic virus type 1; HTLV-2, human T-lymphotropic virus type 2; n.s., non significant.
2 BENITO, GIL, SAHAGÚN ET ALwe reviewed the last 20 years of our hospital liver trans-
plantation registry.METHODS
We conducted a retrospective analysis of all consecutive organ
transplants performed during the last 2 decades at 1 large reference
transplantation unit in Spain. All were tested for anti-HTLV
antibodies.
Over time, HTLV antibody screening was performed using 3
methods: indirect enzyme immunoassay (Abbott, Madrid, Spain),
sandwich enzyme immunoassay (Abbott-Murex, Madrid, Spain),
and, more recently, double sandwich chemiluminescent micropar-
ticle immune assay (Architect, Abbott). All initially HTLV-
seroreactive samples were further tested using confirmatory/
discriminatory Western blot (Genelabs Technologies Inc., Red-
wood City, Calif, United States), line immunoassay (Innogenetics
N.V., Ghent, Belgium), and/or immunoblot (MP Diagnostics,
Copenhagen, Denmark). During the last decade, specific and
discriminatory polymerase chain reaction tests were also used.RESULTS
In Spain, a national case registry has existed for these 2 viral
infections since 1989. To date, 389 individuals with HTLV-1
and 807 with HTLV-2 have been reported nationwide [10].
Table 1 records the main features of these populations. Of
note, whereas 66% of HTLV-1 carriers are immigrants from
Latin America, nearly 90% of HTLV-2epositive patients
are native Spaniards who frequently acknowledged injection
drug use.
A total of 2019 patients were tested for HTLV during the
study period, including 663 potential donors and 1356
recipient candidates. Twelve patients (0.59%) were reactive
on initial HTLV serologic screening. All were native
Spaniards, and 11 were potential transplantation recipients
and 1 was a donor. After discharge from the transplantation
procedure path, only 6 recipients were confirmed as positive
using confirmatory assays and all had HTLV-2 infection.
The remaining patient had either indeterminate or negative
results on repeated testing. Of note, the only donor initially
HTLV-seroreactive was not confirmed as infected.
Two of 6 potential recipients with HTLV-2 underwent
liver transplantation 8 and 4 years ago, respectively. The
latter patient was also positive for human immunodeficiencyvirus. To date, none of them has developed either neuro-
logic or hematologic complications potentially associated
with HTLV-2 infection despite continuous immunosup-
pression with tacrolimus. Likewise, none of the remaining 4
HTLV-2 recipient candidates has developed myelopathy or
lymphomas that could be related to HTLV-2.DISCUSSION
During the last 2 decades, 2019 individuals have been tested
for HTLV, of which 663 were potential donors and 1356
were recipient candidates. Twelve (0.59%) were reactive on
initial HTLV serologic screening, but only 6 (all recipients)
were confirmed as positive, all for HTLV-2. Two underwent
liver transplantation and have remained asymptomatic
despite being on tacrolimus for 4 and 8 years, respectively.
Likewise, the remaining 4 HTLV-2 carriers have not
developed clinical complications potentially associated to
HTLV-2.
Our results suggest that concerns for rapid and frequent
disease development in the transplantation setting should
be restricted to HTLV-1 and does not seem to apply to
HTLV-2. Therefore, the advent of rapid screening diag-
nostic tests specific for HTLV-1 must be considered a pri-
ority as it would reduce unnecessary organ discharge due to
unspecific HTLV-seroreactivity in the transplantation
setting.
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